Baekeland mandate for Parkinson's Disease drug discovery in our CRO
13-07-2020

reMYND’s CRO unit and the Baekelandt lab will submit a Baekeland PhD project (Vlaio) for the development and validation of Parkinson’s disease models for drug discovery. We are currently looking for a motivated PhD student to embark on a 4-year PhD project. If you are interested visit: https://www.kuleuven.be/personeel/jobsite/jobs/55724629

Read more
Interreg. project "Memories" update
01-07-2020

An intermediate update on the progress of identifying differently expressed microRNA in Alzheimer's Disease.

Read more
Approved project ‘Memories’: early diagnostics of Alzheimer’s disease (AD)
08-03-2018

Interreg granted a positive ruling on the project ‘Memories’ mid-December. reMYND will team up with the consortium partners ToxGenSolutions, Icometrix, KU Leuven, Maastricht University and UAntwerpen to support AD research aimed at a sustainable, inclusive growth among Flanders and South-Netherlands. The entire project will receive almost € 800.000 in funding from Interreg. The province of Flemish Brabant will support the project with an additional sum of nearly € 150.000.

Read more
reMYND’s transgenic hTauP301L model of Alzheimer’s disease displays progressive neuronal loss correlating with development of Tau pathology
29-03-2017
Neuronal loss, a pathological hallmark of Alzheimer’s disease, is recapitulated in reMYND’s transgenic human hTauP301L mouse model.
Read more
reMYND’s transgenic hTauP301L model of Alzheimer’s disease displays progressive astrocytosis and microgliosis correlating with development of Tau pathology
14-03-2017
The role of microglia and astrocytes in Alzheimer’s disease and how these contribute to neuronal loss has gained increased interest over the past years.
Read more
A novel transgenic mouse model showing the exacerbating interplay between Abeta- and Tau.P301S-driven pathology
10-06-2016

The interplay of Ab and Tau is still considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease. You can now also assess the effects of your experimental Alzheimer’s Disease treatment on both amyloid- and tau pathology in the cross of our APP-london and Tau.P301S transgenic mouse models, in which APP-london aggravates the Tau-effect.

Read more
reMYND to present on Biotechdag
19-10-2015
reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
Read more
Measuring cognition in reMYND’s Tau animal models
24-06-2015
reMYND’s Tau.P301L and Tau.P301S models feature progressive hyperphosphorylation of Tau with age.
Read more
Longitudinal imaging of Tau aggregates in vivo by two-photon imaging available in reMYND’s Tau.P301S model
06-03-2015
Two-photon imaging allows tracking the formation of Tau aggregates in the same brain-region of a live animal over the course of time.
Read more
Transgenic mouse model of combined Abeta and tau pathology
17-12-2014
The interplay of Abeta and Tau is considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.
Read more